Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England

Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case–control design estimate the relative effectiveness of booster dose BNT162b2 (Pfizer-BioNTech) compared only two-dose primary course (at least 175 days after second dose) or unvaccinated individuals from 13 2021 5 December 2021, when Delta variant was dominant circulation. Outcomes were symptomatic coronavirus disease 2019 (COVID-19) and hospitalization. The against 14–34 mRNA-1273 (Moderna) ChAdOx1-S (AstraZeneca) as ranged around 85% 95%. Absolute vaccine 94% 97% similar all age groups. Limited waning seen 10 more weeks booster. Against hospitalization death, absolute 99% groups irrespective course, no evidence up weeks. This study provides real-world substantially increased protection mild severe course. A analysis data National Immunisation Management System demonstrates significant levels death COVID mRNA following either vaccines.